Amazon Pharmacy to Deliver Eli Lilly's New Oral GLP-1 Weight Loss Pill Same-Day

The gap between a doctor writing a GLP-1 prescription and a patient taking a first dose has historically stretched across days of pharmacy calls, prior-authorization reviews, and delivery waits. Amazon Pharmacy's partnership with Eli Lilly, announced April 9, is engineered specifically to close that window.

Amazon Pharmacy is now dispensing Foundayo, Eli Lilly's recently approved once-daily oral GLP-1 medication indicated for adults with obesity or overweight with weight-related medical problems, with same-day delivery available and transparent pricing built into checkout. For the past three years, the historic boom in GLP-1 weight-loss medications has been plagued by access and affordability bottlenecks, and the Amazon-Lilly arrangement takes direct aim at both.

The pricing structure is the clearest signal of intent. With insurance, Foundayo costs $25 per month, or $1 per day. For cash-pay customers, it is priced at $149 per month, or $5 per day, with manufacturer coupons applied automatically at checkout. That cash price matches what Amazon already charges for Novo Nordisk's Wegovy pill, which Amazon has stocked at its One Medical kiosks since January.

The delivery footprint is designed to scale quickly. Amazon said same-day delivery will be available in nearly 3,000 cities and towns, with plans to expand that access to 4,500 locales by the end of 2026. Next-day and multi-day delivery will cover markets not yet reached by same-day service. Alongside home delivery, Foundayo will be dispensed at pharmacist-supported kiosks inside select One Medical locations, meaning a patient could walk out of a clinic appointment with the medication already in hand.

That last detail is central to the equity argument both companies are making publicly. Laura Steele, Eli Lilly's Group Vice President for U.S. Cardiometabolic Health, put it plainly: "If prescribed, patients may be able to have Foundayo on their doorstep the same day or walk out of their doctor's office with it in-hand in Los Angeles, eliminating the waiting and uncertainty that patients may face when starting their treatment journey."

The clinical profile of Foundayo gives the access argument additional weight. Foundayo received FDA approval as a once-daily tablet that can be taken at any time of day without food or water restrictions. That flexibility removes the administration burden that has made injectable GLP-1s difficult for some patients to maintain. Phase 3 trial data showed patients on the highest dose lost an average of 12.4% of their starting body weight over 72 weeks.

The commercial stakes behind the access narrative are substantial. Lilly's Zepbound generated $4.26 billion in Q4 2025 revenue, up 123% year-over-year, and combined with Mounjaro's $7.41 billion, the two drugs produced $11.67 billion in a single quarter. Foundayo represents a new front in that growth, targeting patients who have resisted or been unable to use injectable therapies.

Observers noted that the logistics advantage Amazon brings to launch could compress the usual ramp-up curve for a new drug, while also raising questions about whether supply chains can keep pace with demand spikes, a problem that disrupted access to earlier GLP-1 injectables. Regulators and payers will be watching utilization patterns closely as Amazon's pharmacy infrastructure, for the first time, becomes a primary access point for a high-demand weight-management drug on its first day of commercial availability.